Launching a 3-pronged immune attack on the tumor microenvironment

Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment. It has recently been discovered that certain pathological cells – but not healthy cells – including cancers with high unmet need and high mortality such as triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors, express tissue factor on the surface of their cell membranes. Several other non-cancerous indications such as endometriosis also highly and selectively express tissue factor.
New Approach
Eikonoklastes Therapeutics has licensed and is developing a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem cells, to trigger complement activation (CDC) and antibody dependent cellular cytotoxicity (ADCC) killing of the pathologic cells. This approach is expected to provide potency and selectivity with minimal side effects.
Superior Technology
Eikonoklastes Therapeutic’s L-ICON3 platform was discovered and engineered by scientific founder, Dr Zhiwei Hu, one of the early pioneers of Tissue Factor targeting therapies. These proprietary, state of the art molecules, were specifically designed based on the shortcomings of the previous generation of the technology and the known toxicities of Antibody-Drug Conjugates. These novel therapies were engineered for maximum efficacy using targeted killing without the need for a toxic payload. The elimination of a toxic payload and all procoagulant activity should deliver a superior safety profile.
Greater potency and selectivity
Improved safety
Immune activation
Disease Opportunity
TF is highly expressed in angiogenesis driven diseases including certain breast and ovarian cancers, melanoma and non-malignant diseases such as endometriosis.
Lead Indication:
Our lead indication is Triple Negative Breast Cancer (TNBC), which accounts for 15% of all breast cancers. TNBC is an aggressive cancer and in most cases considered incurable with 18-month life expectancy from initial diagnosis.
Our leadership team has a sustained record of successful drug development in multibillion-dollar pharmaceutical companies and early-stage biotech ventures as well as deep expertise in Tissue Factor biology.
Bruce Halpryn, PhD
Chief Executive Officer
Sam Lee, MD, MBA, MPH
Chief Business Officer
Mark Dato, MD, PhD
Chief Scientific/Medical Officer
Zhiwei Hu, MD, PhD
Scientific Co-Founder
Contact Us

News And Publications
PRESS RELEASE: Eikonoklastes Therapeutics Closes Oversubscribed Seed Financing to Advance Next-Generation Tissue Factor (TF) Immunotherapies With Initial Focus on Triple-Negative Breast Cancer
Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing. Read More >
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with BRCA1 and BRCA2 mutation. Read More >
Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases
Accumulating evidence suggests that tissue factor (TF) is selectively expressed in pathological angiogenesis-dependent as well as macrophage-associated human diseases. Read More >